AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	21.35	15.65	27.22	12.1	4.07
Short-Term Investments	62.27	91.65	68.84	46.46	-
Cash & Short-Term Investments	83.62	107.3	96.06	58.56	4.07
Cash Growth	-22.07%	11.70%	64.05%	1338.70%	-27.30%
Other Receivables	0.3	1.4	-	-	-
Receivables	0.3	1.4	-	-	-
Prepaid Expenses	2.34	1.81	2.51	1.55	0.16
Other Current Assets	-	-	0.05	-	-
Total Current Assets	86.26	110.51	98.62	60.11	4.23
Long-Term Investments	5.02	27.19	3.22	3.49	-
Long-Term Deferred Charges	-	-	-	1.72	-
Other Long-Term Assets	0.8	1.04	0.72	-	-
Total Assets	92.09	138.74	102.56	65.32	4.23
Accounts Payable	3.32	2.68	2.12	1.06	0.13
Accrued Expenses	6.13	10.7	5.01	2	1.31
Current Portion of Leases	-	-	0.05	-	-
Other Current Liabilities	0.79	0.67	0.01	0.33	0.01
Total Current Liabilities	10.24	14.04	7.19	3.4	1.46
Other Long-Term Liabilities	-	-	0	0.01	0.02
Total Liabilities	10.24	14.04	7.19	3.41	1.48
Additional Paid-In Capital	287.59	278.88	185.47	-	-
Retained Earnings	-205.78	-154.46	-89.72	-47.38	-20.32
Comprehensive Income & Other	0.03	0.28	-0.37	-0.03	-
Total Common Equity	81.85	124.7	95.37	-47.41	-20.32
Shareholders' Equity	81.85	124.7	95.37	61.91	2.75
Total Liabilities & Equity	92.09	138.74	102.56	65.32	4.23
Total Debt	-	-	0.05	-	-
Net Cash (Debt)	83.62	107.3	96.01	58.56	4.07
Net Cash Growth	-22.07%	11.76%	63.96%	1338.70%	-16.43%
Net Cash Per Share	2.80	4.55	6.26	22.20	1.58
Filing Date Shares Outstanding	30.1	29.77	19.4	2.73	2.71
Total Common Shares Outstanding	29.92	29.74	19.4	2.73	2.71
Working Capital	76.02	96.46	91.44	56.71	2.78
Book Value Per Share	2.74	4.19	4.92	-17.36	-7.50
Tangible Book Value	81.85	124.7	95.37	-47.41	-20.32
Tangible Book Value Per Share	2.74	4.19	4.92	-17.36	-7.50

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q